Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Cardiovascular
Immunology
Neuroscience
Oncology
sabatolimab - TIM3 antagonist
NCT04266301 STIMULUS-MDS2 (CMBG453B12301)
Indication
Myelodysplastic syndrome
Phase
Phase 3
Patients
500
Primary
Overall survival
Outcome
Measures
Arms
Intervention
Sabatolimab 800 mg + azacitidine 75 mg/m2
Sabatolimab 800 mg + azacitidine 75 mg/m2 + placebo
Patients with intermediate, high or very high risk Myelodysplastic Syndrome
(MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Target
Patients
Read-out
Milestone(s)
2024
Publication
TBD
78 Investor Relations | Q3 2022 Results
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation